Aurobindo Pharma gets USFDA nod for infections treatment drug
Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Azithromycin oral suspension
New Delhi: Drug firm Aurobindo Pharma Thursday said it has received final nod from the US health regulator for its Azithromycin oral suspension used for treatment of infections.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Azithromycin oral suspension 100 mg /5 mL and 200 mg/5 mL, Aurobindo Pharma said in a statement.
The product is a generic version of Pfizer Inc’s Zithromax oral suspension, it added.
“The product will be launched in November 2018,” Aurobindo Pharma said.
Azithromycin oral suspension is indicated for the treatment of patients with mild to moderate infections, it added.
According to IQVIA, the approved product has an estimated market size of $71 million for the 12 months ending August 2018, Aurobindo Pharma said.
The company now has a total of 386 abbreviated new drug application (ANDA) approvals (357 final approvals including 19 from Aurolife Pharma LLC and 29 tentative approvals) from the USFDA, it added.
Shares of Aurobindo Pharma were trading at Rs 773.75 per scrip on the BSE, down by 0.58% from its previous close.
- Oil prices rise on Asian stock rally, OPEC-led cuts
- RBI governor Shaktikanta Das: Once beaten, second time lucky
- Detention of Nissan’s Carlos Ghosn extended through 20 December
- India to add 10GW of renewable power in FY20: ICRA
- Flipkart to invest in furniture, groceries; claims to be a market leader in e-commerce
Editor's Picks »
- Shaktikanta Das assumes charge as 25th RBI governor
- MP elections 2018: BJP says will not stake claim to form govt; SP, BSP to support Congress
- Indian Railways to discontinue mela surcharge
- GoAir offers flight tickets from Rs 1,415 on new route
- Reliance Jio board approves plan to hive-off fibre, tower assets to separate entities
- Escorts: Japanese joint venture to hone growth in tractors
- HCL Tech’s acquisition of IBM products raises more questions than answers
- Investors ignore NMDC’s price cuts, and worry about its Donimalai iron ore mine instead
- Steel stocks get winter chill as China demand issues resurface
- Why Uday Kotak’s defiance is scaring his bank’s investors